You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameSuprofen
Accession NumberDB00870  (APRD00230)
TypeSmall Molecule
GroupsApproved, Withdrawn
DescriptionAn ibuprofen-type anti-inflammatory analgesic and antipyretic. It inhibits prostaglandin synthesis and has been proposed as an anti-arthritic. It is no longer approved for use in the United States.
Structure
Thumb
Synonyms
(+-)-2-(P-(2-Thenoyl)phenyl)propionic acid
2-(4-(2-Thenoyl)phenyl)propionsaeure
2-[4-(Thiophene-2-carbonyl)-phenyl]-propionic acid
4-(2-Thenoyl)hydratropsaeure
alpha-Methyl-4-(2-thienylcarbonyl)benzeneacetic acid
P-2-Thenoylhydratropic acid
PROFENAL
Suprofen
Suprofène
Suprofene
Suprofeno
Suprofenum
SUTOPROFEN
External Identifiers
  • R 25061
  • TN 762
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ProfenalJanssen Pharmaceuticals
SrendamPola Pharma
SulprotinTaiyo Pharmaceutical
TopalgicAlfresa Pharma
Brand mixturesNot Available
SaltsNot Available
Categories
UNII988GU2F9PE
CAS number40828-46-4
WeightAverage: 260.308
Monoisotopic: 260.05071494
Chemical FormulaC14H12O3S
InChI KeyMDKGKXOCJGEUJW-UHFFFAOYSA-N
InChI
InChI=1S/C14H12O3S/c1-9(14(16)17)10-4-6-11(7-5-10)13(15)12-3-2-8-18-12/h2-9H,1H3,(H,16,17)
IUPAC Name
2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid
SMILES
CC(C(O)=O)C1=CC=C(C=C1)C(=O)C1=CC=CS1
Pharmacology
IndicationUsed as eye drops to inhibit the miosis (pupil constriction) that may occur during ocular surgery.
Structured Indications Not Available
PharmacodynamicsSuprofen is a non-steroidal anti-inflammatory analgesic and antipyretic. Ophthalmic anti-inflammatory medicines are used in the eye to lessen problems that can occur during or after some kinds of eye surgery. Sometimes, the pupil of the eye gets smaller during an operation (pupil constriction), making it more difficult for the surgeon to reach some areas of the eye. Suprofen is used to help prevent this.
Mechanism of actionSuprofen binds to the cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) isoenzymes, preventing the synthesis of prostaglandins and reducing the inflammatory response. Cyclooxygenase catalyses the formation of prostaglandins and thromboxane from arachidonic acid (itself derived from the cellular phospholipid bilayer by phospholipase A2). Prostaglandins act (among other things) as messenger molecules in the process of inflammation. The overall result is a reduction in pain and inflammation in the eyes and the prevention of pupil constriction during surgery. Normally trauma to the anterior segment of the eye (especially the iris) increases endogenous prostaglandin synthesis which leads to constriction of the iris sphincter.
TargetKindPharmacological actionActionsOrganismUniProt ID
Prostaglandin G/H synthase 1Proteinyes
inhibitor
HumanP23219 details
Prostaglandin G/H synthase 2Proteinyes
inhibitor
HumanP35354 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein binding20%
Metabolism

Primarily hepatic (mainly via cytochrome P450 isozyme 2C9).

SubstrateEnzymesProduct
Suprofen
Suprofen S-oxideDetails
Suprofen
Thiophene-4,5-epoxideDetails
Suprofen
Suprofen glucuronideDetails
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicitySymptoms of overdose include bleeding in the eye or redness or swelling of the eye or the eyelid, blurred vision or other change in vision, fever or chills, itching or tearing, nausea or vomiting, pain, sensitivity to light, shortness of breath, sticky or matted eyelashes, swelling of face, throbbing pain, tightness in chest, troubled breathing, and wheezing.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Suprofen Action PathwayDrug actionSMP00101
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Suprofen is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Suprofen is combined with 19-norandrostenedione.Experimental, Illicit
4-AndrostenedioneThe risk or severity of adverse effects can be increased when Suprofen is combined with 4-Androstenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Suprofen is combined with 5-androstenedione.Experimental, Illicit
AbciximabSuprofen may increase the anticoagulant activities of Abciximab.Approved
AbirateroneThe metabolism of Suprofen can be decreased when combined with Abiraterone.Approved
AcebutololSuprofen may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Suprofen is combined with Aceclofenac.Approved
AcenocoumarolSuprofen may increase the anticoagulant activities of Acenocoumarol.Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Suprofen is combined with Acetovanillone.Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Suprofen is combined with Acetylsalicylic acid.Approved, Vet Approved
AclarubicinSuprofen may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Suprofen.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Suprofen is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Suprofen is combined with Aldosterone.Experimental
Alendronic acidThe risk or severity of adverse effects can be increased when Suprofen is combined with Alendronic acid.Approved
AliskirenSuprofen may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlprenololSuprofen may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Suprofen.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Suprofen is combined with Amcinonide.Approved
AmikacinSuprofen may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideSuprofen may decrease the antihypertensive activities of Amiloride.Approved
AmiodaroneThe metabolism of Suprofen can be decreased when combined with Amiodarone.Approved, Investigational
AmrubicinSuprofen may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodSuprofen may increase the anticoagulant activities of Ancrod.Investigational
AnecortaveThe risk or severity of adverse effects can be increased when Suprofen is combined with Anecortave.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Suprofen is combined with Anisodamine.Investigational
annamycinSuprofen may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Suprofen is combined with Antipyrine.Approved
Antithrombin III humanSuprofen may increase the anticoagulant activities of Antithrombin III human.Approved
Aop200704Suprofen may decrease the antihypertensive activities of Aop200704.Investigational
ApixabanSuprofen may increase the anticoagulant activities of Apixaban.Approved
ApramycinSuprofen may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Suprofen is combined with Apremilast.Approved, Investigational
AprepitantThe metabolism of Suprofen can be increased when combined with Aprepitant.Approved, Investigational
ArbekacinSuprofen may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
ArdeparinSuprofen may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanSuprofen may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololSuprofen may decrease the antihypertensive activities of Arotinolol.Approved
AtenololSuprofen may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Suprofen is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Suprofen is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Suprofen.Approved
BalsalazideSuprofen may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BecaplerminSuprofen may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BeclomethasoneThe risk or severity of adverse effects can be increased when Suprofen is combined with Beclomethasone.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Suprofen is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololSuprofen may decrease the antihypertensive activities of Befunolol.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Suprofen.Approved, Investigational
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Suprofen.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Benoxaprofen.Withdrawn
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Suprofen.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Suprofen is combined with Betamethasone.Approved, Vet Approved
BetaxololSuprofen may decrease the antihypertensive activities of Betaxolol.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Suprofen is combined with Betulinic Acid.Investigational
BevantololSuprofen may decrease the antihypertensive activities of Bevantolol.Approved
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Suprofen.Approved, Investigational
BisoprololSuprofen may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinSuprofen may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololSuprofen may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Suprofen is combined with Bromfenac.Approved
BucillamineThe risk or severity of adverse effects can be increased when Suprofen is combined with Bucillamine.Investigational
BucindololSuprofen may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Suprofen is combined with Budesonide.Approved
BufuralolSuprofen may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumetanideSuprofen may decrease the diuretic activities of Bumetanide.Approved
BupranololSuprofen may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Suprofen.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Suprofen.Experimental
CapecitabineThe metabolism of Suprofen can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Suprofen.Approved
CarbamazepineThe metabolism of Suprofen can be increased when combined with Carbamazepine.Approved, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Suprofen.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Suprofen.Approved, Vet Approved, Withdrawn
CarteololSuprofen may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolSuprofen may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Suprofen is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Suprofen is combined with Celecoxib.Approved, Investigational
CeliprololSuprofen may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Suprofen can be increased when it is combined with Ceritinib.Approved
CertoparinSuprofen may increase the anticoagulant activities of Certoparin.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Suprofen.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Suprofen.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Suprofen.Approved
CholecalciferolThe metabolism of Suprofen can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholestyramineCholestyramine can cause a decrease in the absorption of Suprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Suprofen is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Suprofen.Approved
CinoxacinSuprofen may increase the neuroexcitatory activities of Cinoxacin.Approved, Withdrawn
CiprofloxacinSuprofen may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
Citric AcidSuprofen may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Suprofen is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Suprofen is combined with Clobetasol propionate.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Suprofen is combined with Clocortolone.Approved
ClodronateThe risk or severity of adverse effects can be increased when Suprofen is combined with Clodronate.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Suprofen is combined with Clonixin.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Suprofen.Vet Approved
ClotrimazoleThe metabolism of Suprofen can be decreased when combined with Clotrimazole.Approved, Vet Approved
ColesevelamColesevelam can cause a decrease in the absorption of Suprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Suprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Suprofen is combined with Cortisone acetate.Approved
CurcuminThe risk or severity of adverse effects can be increased when Suprofen is combined with Curcumin.Investigational
CyclosporineSuprofen may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
CyclosporineThe metabolism of Suprofen can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Suprofen is combined with D-Limonene.Investigational
Dabigatran etexilateSuprofen may increase the anticoagulant activities of Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Suprofen can be decreased when it is combined with Dabrafenib.Approved
DalteparinSuprofen may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidSuprofen may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DaunorubicinSuprofen may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Suprofen is combined with Deferasirox.Approved, Investigational
dehydroepiandrosterone sulfateThe risk or severity of adverse effects can be increased when Suprofen is combined with dehydroepiandrosterone sulfate.Investigational
DelavirdineThe metabolism of Suprofen can be decreased when combined with Delavirdine.Approved
DesirudinSuprofen may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Suprofen is combined with Desmopressin.Approved
DesoximetasoneThe risk or severity of adverse effects can be increased when Suprofen is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Suprofen is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Suprofen is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Suprofen is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Suprofen is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Suprofen.Approved
DextranSuprofen may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Suprofen may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Suprofen may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Suprofen may increase the anticoagulant activities of Dextran 75.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Suprofen.Approved, Vet Approved
DicoumarolSuprofen may increase the anticoagulant activities of Dicoumarol.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Suprofen is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Suprofen.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Suprofen is combined with Difluocortolone.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Suprofen is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Suprofen.Approved
DihydrostreptomycinSuprofen may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Suprofen.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Suprofen.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Suprofen.Approved
DoxorubicinSuprofen may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneSuprofen may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Suprofen is combined with Droxicam.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Suprofen is combined with Duvelisib.Investigational
E6201The risk or severity of adverse effects can be increased when Suprofen is combined with E6201.Investigational
EbselenThe risk or severity of adverse effects can be increased when Suprofen is combined with Ebselen.Investigational
Edetic AcidSuprofen may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanSuprofen may increase the anticoagulant activities of Edoxaban.Approved
EfavirenzThe metabolism of Suprofen can be decreased when combined with Efavirenz.Approved, Investigational
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Suprofen.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Suprofen.Approved
EnoxacinSuprofen may increase the neuroexcitatory activities of Enoxacin.Approved
EnoxaparinSuprofen may increase the anticoagulant activities of Enoxaparin.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Suprofen is combined with Epirizole.Approved
EpirubicinSuprofen may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneSuprofen may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Suprofen.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Suprofen.Approved
EquileninThe risk or severity of adverse effects can be increased when Suprofen is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Suprofen is combined with Equilin.Approved
EsmololSuprofen may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Suprofen is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Suprofen is combined with Estrone sulfate.Approved
Etacrynic acidSuprofen may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Suprofen.Approved, Investigational
Ethyl biscoumacetateSuprofen may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Suprofen is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Suprofen is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Suprofen is combined with Etofenamate.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Suprofen is combined with Etoricoxib.Approved, Investigational
EtravirineThe metabolism of Suprofen can be decreased when combined with Etravirine.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Suprofen is combined with Evening primrose oil.Approved
exisulindThe risk or severity of adverse effects can be increased when Suprofen is combined with exisulind.Investigational
FenbufenThe risk or severity of adverse effects can be increased when Suprofen is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Suprofen.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Suprofen.Vet Approved
FleroxacinSuprofen may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Suprofen.Approved, Withdrawn
FloxuridineThe metabolism of Suprofen can be decreased when combined with Floxuridine.Approved
fluasteroneThe risk or severity of adverse effects can be increased when Suprofen is combined with fluasterone.Investigational
FluconazoleThe metabolism of Suprofen can be decreased when combined with Fluconazole.Approved
FludrocortisoneThe risk or severity of adverse effects can be increased when Suprofen is combined with Fludrocortisone.Approved
FluindioneSuprofen may increase the anticoagulant activities of Fluindione.Investigational
FlumequineSuprofen may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Suprofen is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Suprofen is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Suprofen is combined with Flunixin.Vet Approved
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Suprofen is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Suprofen is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Suprofen is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Suprofen is combined with Fluorometholone.Approved
FluorouracilThe metabolism of Suprofen can be decreased when combined with Fluorouracil.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Suprofen is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Suprofen is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Suprofen.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Suprofen is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Suprofen.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Suprofen is combined with Fluticasone furoate.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Suprofen is combined with Fluticasone Propionate.Approved
FluvastatinThe metabolism of Suprofen can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Suprofen can be decreased when combined with Fluvoxamine.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Suprofen.Approved, Nutraceutical, Vet Approved
FondaparinuxSuprofen may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumSuprofen may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Suprofen.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Suprofen is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Suprofen.Approved
FosphenytoinThe metabolism of Suprofen can be increased when combined with Fosphenytoin.Approved
FramycetinSuprofen may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideSuprofen may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabexateSuprofen may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinSuprofen may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinSuprofen may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Suprofen.Approved, Withdrawn
GemfibrozilThe metabolism of Suprofen can be decreased when combined with Gemfibrozil.Approved
GemifloxacinSuprofen may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinSuprofen may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinSuprofen may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1ASuprofen may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GrepafloxacinSuprofen may increase the neuroexcitatory activities of Grepafloxacin.Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Suprofen is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Suprofen is combined with HE3286.Investigational
HeparinSuprofen may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Suprofen is combined with Higenamine.Investigational
HirulogSuprofen may increase the anticoagulant activities of Hirulog.Experimental
HMPL-004The risk or severity of adverse effects can be increased when Suprofen is combined with HMPL-004.Investigational
HydralazineSuprofen may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Suprofen.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Suprofen is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Suprofen.Approved
Hygromycin BSuprofen may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Suprofen is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Suprofen is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Suprofen is combined with Icatibant.Approved
IdarubicinSuprofen may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
idraparinuxSuprofen may increase the anticoagulant activities of idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Suprofen.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Suprofen.Investigational
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Suprofen.Approved
IndenololSuprofen may decrease the antihypertensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Suprofen can be decreased when combined with Indinavir.Approved
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Suprofen.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Indoprofen.Withdrawn
INNO-206Suprofen may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
IrbesartanThe metabolism of Suprofen can be decreased when combined with Irbesartan.Approved, Investigational
IsoxicamThe risk or severity of adverse effects can be increased when Suprofen is combined with Isoxicam.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Suprofen is combined with Istaroxime.Investigational
KanamycinSuprofen may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Suprofen is combined with Kebuzone.Experimental
KetoconazoleThe metabolism of Suprofen can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Suprofen.Approved
LabetalolSuprofen may decrease the antihypertensive activities of Labetalol.Approved
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Suprofen.Approved, Investigational
LeflunomideThe metabolism of Suprofen can be decreased when combined with Leflunomide.Approved, Investigational
LepirudinSuprofen may increase the anticoagulant activities of Lepirudin.Approved
LevobunololSuprofen may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinSuprofen may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Suprofen.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Suprofen.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Suprofen is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Suprofen.Approved
LomefloxacinSuprofen may increase the neuroexcitatory activities of Lomefloxacin.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Suprofen is combined with Lornoxicam.Approved
LosartanThe metabolism of Suprofen can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Suprofen can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Loxoprofen.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Suprofen.Approved, Investigational
LumacaftorThe serum concentration of Suprofen can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Suprofen is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Suprofen.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Suprofen is combined with Magnesium salicylate.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Suprofen.Approved
ME-609The risk or severity of adverse effects can be increased when Suprofen is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Suprofen is combined with Meclofenamic acid.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Suprofen is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Suprofen.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Suprofen is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Suprofen.Approved, Vet Approved
MesalazineSuprofen may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Suprofen is combined with Metamizole.Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Suprofen.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Suprofen.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Suprofen is combined with Methylprednisolone.Approved, Vet Approved
MetipranololSuprofen may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Suprofen.Approved
MetoprololSuprofen may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideSuprofen may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MifepristoneThe serum concentration of Suprofen can be increased when it is combined with Mifepristone.Approved, Investigational
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Suprofen.Approved
MizoribineThe risk or severity of adverse effects can be increased when Suprofen is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Suprofen.Approved
MometasoneThe risk or severity of adverse effects can be increased when Suprofen is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Suprofen.Approved
MoxifloxacinSuprofen may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Suprofen.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Suprofen is combined with Mycophenolic acid.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Suprofen is combined with Nabumetone.Approved
NadololSuprofen may decrease the antihypertensive activities of Nadolol.Approved
NadroparinSuprofen may increase the anticoagulant activities of Nadroparin.Approved
NafamostatSuprofen may increase the anticoagulant activities of Nafamostat.Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Suprofen.Approved
Nalidixic AcidSuprofen may increase the neuroexcitatory activities of Nalidixic Acid.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Suprofen.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Suprofen is combined with NCX 1022.Investigational
NCX 4016The risk or severity of adverse effects can be increased when Suprofen is combined with NCX 4016.Investigational
NeamineSuprofen may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NemonoxacinSuprofen may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinSuprofen may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Suprofen is combined with Nepafenac.Approved
NetilmicinSuprofen may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
NicardipineThe metabolism of Suprofen can be decreased when combined with Nicardipine.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Suprofen is combined with Niflumic Acid.Approved
NimesulideThe risk or severity of adverse effects can be increased when Suprofen is combined with Nimesulide.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Suprofen is combined with Nitroaspirin.Investigational
NorfloxacinSuprofen may increase the neuroexcitatory activities of Norfloxacin.Approved
OfloxacinSuprofen may increase the neuroexcitatory activities of Ofloxacin.Approved
Oleoyl estroneThe risk or severity of adverse effects can be increased when Suprofen is combined with Oleoyl estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Suprofen.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Suprofen.Approved
OlsalazineSuprofen may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Suprofen is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Suprofen.Investigational
OmeprazoleThe metabolism of Suprofen can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OrgoteinThe risk or severity of adverse effects can be increased when Suprofen is combined with Orgotein.Vet Approved
OtamixabanSuprofen may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Suprofen is combined with Oxaprozin.Approved
OxprenololSuprofen may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Suprofen is combined with Oxyphenbutazone.Withdrawn
PamidronateThe risk or severity of adverse effects can be increased when Suprofen is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Suprofen is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Suprofen is combined with Parecoxib.Approved
ParomomycinSuprofen may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
PazufloxacinSuprofen may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinSuprofen may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololSuprofen may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentosan PolysulfateSuprofen may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Suprofen.Approved
PhenindioneSuprofen may increase the anticoagulant activities of Phenindione.Approved
PhenobarbitalThe metabolism of Suprofen can be increased when combined with Phenobarbital.Approved
PhenprocoumonSuprofen may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Suprofen.Approved, Vet Approved
PhenytoinThe metabolism of Suprofen can be increased when combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Suprofen.Approved, Investigational
PindololSuprofen may decrease the antihypertensive activities of Pindolol.Approved
PirarubicinSuprofen may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideSuprofen may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Suprofen is combined with Pirfenidone.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Suprofen.Approved, Investigational
PlicamycinSuprofen may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Suprofen.Approved
PractololSuprofen may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Suprofen.Approved
PrasteroneThe risk or severity of adverse effects can be increased when Suprofen is combined with Prasterone.Approved, Nutraceutical
PrednicarbateThe risk or severity of adverse effects can be increased when Suprofen is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Suprofen is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Suprofen is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Suprofen is combined with Pregnenolone.Experimental
PrimidoneThe metabolism of Suprofen can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Suprofen can be increased when it is combined with Probenecid.Approved
PropacetamolThe risk or severity of adverse effects can be increased when Suprofen is combined with Propacetamol.Approved
PropranololSuprofen may decrease the antihypertensive activities of Propranolol.Approved, Investigational
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Suprofen.Experimental
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Suprofen.Experimental, Investigational
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Suprofen.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Suprofen.Vet Approved
Protein CSuprofen may increase the anticoagulant activities of Protein C.Approved
Protein S humanSuprofen may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeSuprofen may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinSuprofen may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when Suprofen is combined with PTC299.Investigational
PuromycinSuprofen may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
PyrimethamineThe metabolism of Suprofen can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Suprofen.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Suprofen.Approved
QuinineThe metabolism of Suprofen can be decreased when combined with Quinine.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Suprofen.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Suprofen.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Suprofen is combined with Resveratrol.Experimental, Investigational
ReviparinSuprofen may increase the anticoagulant activities of Reviparin.Approved
RibostamycinSuprofen may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
RifampicinThe metabolism of Suprofen can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Suprofen can be increased when combined with Rifapentine.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Suprofen is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Suprofen is combined with Risedronate.Approved, Investigational
RivaroxabanSuprofen may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Suprofen is combined with Rofecoxib.Investigational, Withdrawn
RosoxacinSuprofen may increase the neuroexcitatory activities of Rosoxacin.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Suprofen.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Suprofen is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Suprofen is combined with Salicylic acid.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Suprofen is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Suprofen.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Suprofen.Investigational
SecobarbitalThe metabolism of Suprofen can be increased when combined with Secobarbital.Approved, Vet Approved
SeratrodastThe risk or severity of adverse effects can be increased when Suprofen is combined with Seratrodast.Approved, Investigational
SildenafilThe metabolism of Suprofen can be decreased when combined with Sildenafil.Approved, Investigational
SisomicinSuprofen may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SorafenibThe metabolism of Suprofen can be decreased when combined with Sorafenib.Approved, Investigational
SotalolSuprofen may decrease the antihypertensive activities of Sotalol.Approved
SP1049CSuprofen may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinSuprofen may increase the neuroexcitatory activities of Sparfloxacin.Approved
SpectinomycinSuprofen may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Suprofen.Approved
SpironolactoneSuprofen may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when Suprofen is combined with SRT501.Investigational
StreptomycinSuprofen may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinSuprofen may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfadiazineThe metabolism of Suprofen can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Suprofen can be decreased when combined with Sulfamethoxazole.Approved
SulfasalazineSuprofen may increase the nephrotoxic activities of Sulfasalazine.Approved
SulfisoxazoleThe metabolism of Suprofen can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Suprofen.Approved
SulodexideSuprofen may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Suprofen.Investigational
TacrolimusSuprofen may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Suprofen.Approved
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Suprofen.Approved
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Suprofen.Approved
Technetium tc 99m etidronateThe risk or severity of adverse effects can be increased when Suprofen is combined with Technetium tc 99m etidronate.Approved
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Suprofen is combined with Technetium Tc-99m Medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Suprofen.Approved, Investigational
TemafloxacinSuprofen may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Suprofen.Experimental, Investigational
TenofovirThe risk or severity of adverse effects can be increased when Suprofen is combined with Tenofovir.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Suprofen.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Suprofen is combined with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Suprofen is combined with Teriflunomide.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Suprofen is combined with Tiaprofenic acid.Approved
TicagrelorThe metabolism of Suprofen can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Suprofen can be decreased when combined with Ticlopidine.Approved
TiludronateThe risk or severity of adverse effects can be increased when Suprofen is combined with Tiludronate.Approved, Vet Approved
TimololSuprofen may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Suprofen is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Suprofen is combined with Tixocortol.Approved
TobramycinSuprofen may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TolbutamideThe metabolism of Suprofen can be decreased when combined with Tolbutamide.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Suprofen is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Suprofen.Approved
TorasemideSuprofen may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Suprofen.Approved
TranilastThe risk or severity of adverse effects can be increased when Suprofen is combined with Tranilast.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Suprofen.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Suprofen.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Suprofen is combined with Triamcinolone.Approved, Vet Approved
TriamtereneSuprofen may decrease the antihypertensive activities of Triamterene.Approved
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Suprofen.Approved, Vet Approved
TrimethoprimThe metabolism of Suprofen can be decreased when combined with Trimethoprim.Approved, Vet Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Suprofen is combined with Trisalicylate-choline.Approved
TrovafloxacinSuprofen may increase the neuroexcitatory activities of Trovafloxacin.Approved, Withdrawn
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Suprofen.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Suprofen is combined with Valdecoxib.Investigational, Withdrawn
Valproic AcidThe metabolism of Suprofen can be decreased when combined with Valproic Acid.Approved, Investigational
ValrubicinSuprofen may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe metabolism of Suprofen can be decreased when combined with Valsartan.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Suprofen.Approved
VoriconazoleThe metabolism of Suprofen can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinSuprofen may increase the anticoagulant activities of Warfarin.Approved
XimelagatranSuprofen may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Ym150Suprofen may increase the anticoagulant activities of Ym150.Investigational
ZafirlukastThe metabolism of Suprofen can be decreased when combined with Zafirlukast.Approved, Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Zaltoprofen.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Suprofen.Approved, Investigational, Withdrawn
Zoledronic acidThe risk or severity of adverse effects can be increased when Suprofen is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Suprofen is combined with Zomepirac.Withdrawn
ZorubicinSuprofen may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesM01AE07
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (50.8 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9927
Blood Brain Barrier+0.9289
Caco-2 permeable+0.6039
P-glycoprotein substrateNon-substrate0.7298
P-glycoprotein inhibitor INon-inhibitor0.9534
P-glycoprotein inhibitor IINon-inhibitor0.9664
Renal organic cation transporterNon-inhibitor0.8998
CYP450 2C9 substrateNon-substrate0.6293
CYP450 2D6 substrateNon-substrate0.9226
CYP450 3A4 substrateNon-substrate0.8098
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.8607
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.8958
CYP450 3A4 inhibitorNon-inhibitor0.9526
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8682
Ames testNon AMES toxic0.9398
CarcinogenicityNon-carcinogens0.7568
BiodegradationReady biodegradable0.7714
Rat acute toxicity3.1892 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9869
hERG inhibition (predictor II)Non-inhibitor0.9716
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Alcon laboratories inc
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point124.3 °CPhysProp
water solubilitylimited solubilityNot Available
logP2.2Not Available
pKa3.91MERCK INDEX (1996)
Predicted Properties
PropertyValueSource
Water Solubility0.0422 mg/mLALOGPS
logP3.16ALOGPS
logP3.53ChemAxon
logS-3.8ALOGPS
pKa (Strongest Acidic)4.01ChemAxon
pKa (Strongest Basic)-7.8ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area54.37 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity69.41 m3·mol-1ChemAxon
Polarizability26.84 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylpropanoic acids. These are compounds with a structure containing a benzene ring conjugated to a propanoic acid.
KingdomOrganic compounds
Super ClassPhenylpropanoids and polyketides
ClassPhenylpropanoic acids
Sub ClassNot Available
Direct ParentPhenylpropanoic acids
Alternative Parents
Substituents
  • 2-phenylpropanoic-acid
  • Phenylacetate
  • Monoterpenoid
  • Monocyclic monoterpenoid
  • Aromatic monoterpenoid
  • P-cymene
  • Acetophenone
  • Aryl ketone
  • Thiophene carboxylic acid or derivatives
  • Benzoyl
  • Benzenoid
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Thiophene
  • Ketone
  • Organoheterocyclic compound
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Carbonyl group
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Loll PJ, Picot D, Ekabo O, Garavito RM: Synthesis and use of iodinated nonsteroidal antiinflammatory drug analogs as crystallographic probes of the prostaglandin H2 synthase cyclooxygenase active site. Biochemistry. 1996 Jun 11;35(23):7330-40. [PubMed:8652509 ]
  2. Bender A, Scheiber J, Glick M, Davies JW, Azzaoui K, Hamon J, Urban L, Whitebread S, Jenkins JL: Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure. ChemMedChem. 2007 Jun;2(6):861-73. [PubMed:17477341 ]
  3. Llorens O, Perez JJ, Palomer A, Mauleon D: Differential binding mode of diverse cyclooxygenase inhibitors. J Mol Graph Model. 2002 Mar;20(5):359-71. [PubMed:11885959 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Llorens O, Perez JJ, Palomer A, Mauleon D: Differential binding mode of diverse cyclooxygenase inhibitors. J Mol Graph Model. 2002 Mar;20(5):359-71. [PubMed:11885959 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the IX-alpha-C8 and IX-alpha-C12 monoconjugates and diconjugate. Is also able to catalyze the glucuronidation of 17beta-estradiol, 17alpha-ethinylestradiol, 1-hydroxypyrene, 4-methylumbelliferone, 1-naph...
Gene Name:
UGT1A1
Uniprot ID:
P22309
Molecular Weight:
59590.91 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Glucuronosyltransferase activity
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.Its unique specificity for 3,4-catechol estrogens and estriol suggests it may play an important role in regulating the level and activity of these potent and active estrogen metabolites. Is also active with androsterone, hyodeoxycholic acid and tetrachlorocatechol...
Gene Name:
UGT2B7
Uniprot ID:
P16662
Molecular Weight:
60694.12 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23